Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - ISIS Pharmaceuticals (NasdaqNM:ISIP)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 28Price hit new 52-week high ($17.10)
Aug 22Conference call: Isis Pharmaceuticals, Inc. Discusses the Strategic Alliance Formed by Isis and Eli Lilly and Company
Aug  9Conference call: GeneTrove Database Introduction
July 25Conference call: Isis Pharmaceuticals Incorporated 2nd Quarter Earnings
Location
2292 Faraday Avenue
Carlsbad, CA 92008
Phone: (760) 931-9200
Fax: (760) 931-9639
Email: info@isisph.com
Employees (last reported count): 303
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 41%
·Institutional: 38% (65% of float)
(129 institutions)
·Net Inst. Buying: 56.0K shares
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
ISIS Pharmaceuticals, Inc. is engaged in genomics-based drug discovery and development focused on RNA (ribonucleic acid). RNA contains all of the information the cell needs to produce proteins. Interaction with RNA can keep disease-causing proteins from being produced. The Company has integrated its expertise in molecular and cellular biology, medicinal chemistry, RNA biochemistry, bioinformatics, pharmacology and clinical development to create two technologies. Antisense, the Company's leading technology, directly uses gene-sequencing information to rationally design drugs. From this technology, the Company has put one product on the market and built a robust pipeline of 11 products in development, of which six products are in late stage clinical trials (either Phase II or Phase III).
More from Market Guide: Expanded Business Description

Financial Summary
ISIS Pharmaceuticals is engaged in the discovery and development of a new class of drugs, antisense oligonucleotides, which may form a new basis for therapeutic drugs that are safer and more effective. For the six months ended 6/30/01, revenues rose 11% to $12.2 million. Net loss applicable to Common rose 40% to $46.5 million. Revenues reflect the licensing of preclinical Type two diabetes antisense drug candidate. Net loss reflects increased R&D expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Stanley Crooke, M.D., Ph.D., 56
Chairman, CEO, and Pres
$658K--  
B. Lynne Parshall, 46
CFO, Exec. VP, Sec., Director
503K$1.6M
Patricia Lowenstam, 54
VP, HR
--  --  
Karen Lundstedt, 36
VP, Investor Relations & Corp. Communications
--  --  
C. Frank Bennett, Ph.D., 44
VP, Biology
311K72K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ISIPAs of 31-Aug-2001
Price and Volume
52-Week Low
on 4-Apr-2001
$7.875
Recent Price$16.30 
52-Week High
on 28-Aug-2001
$17.10 
Beta0.93 
Daily Volume (3-month avg)350.2K
Daily Volume (10-day avg)1.18M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+25.4%
52-Week Change
relative to S&P500
+68.2%
Share-Related Items
Market Capitalization$688.6M
Shares Outstanding42.2M
Float24.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.52 
Earnings (ttm)-$1.70 
Earnings (mrq)-$0.58 
Sales (ttm)$0.97 
Cash (mrq)$2.52 
Valuation Ratios
Price/Book (mrq)31.45 
Price/EarningsN/A 
Price/Sales (ttm)16.82 
Income Statements
Sales (ttm)$38.4M
EBITDA (ttm)-$41.7M
Income available to common (ttm)-$68.0M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-37.59%
Return on Equity (ttm)-199.09%
Financial Strength
Current Ratio (mrq)4.28 
Debt/Equity (mrq)2.80 
Total Cash (mrq)$106.3M
Short Interest
As of 8-Aug-2001
Shares Short3.38M
Percent of Float13.6%
Shares Short
(Prior Month)
3.51M
Short Ratio17.41 
Daily Volume194.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.